2026Research-grant programme / portfolio18 total BSRA Small Research Grants announced for 2026; 15 identified as DoNotAge.org-funded
DoNotAge.org–BSRA Small Research Grants 2026 — 15 Awards
British Society for Research on Ageing (BSRA)
BSRA announced 18 Small Research Grants across 13 UK institutions in 2026. Alan Graves stated that DoNotAge.org funded 15 of those projects; Quest NutraPharma also sponsored the programme.
BSRA's 2026 Small Research Grants programme awarded 18 projects across 13 UK institutions. DoNotAge.org funded 15 projects, while Quest NutraPharma also supported the programme. The total BSRA award count should not be presented as 18 DoNotAge-funded projects.
Primary source ↗
2026DoNotAge.org–BSRA Small Research GrantDoNotAge.org-BSRA award confirmed. Related study ISRCTN64669648 has a 2026 peer-reviewed protocol; no clinical efficacy result is established by that publication.
Joanna Ward — Cardiovascular Disease and Inflammation in Ageing
University of Lincoln
BSRA identifies Joanna Ward as a recipient of a DoNotAge.org-BSRA Small Research Grant in 2026.
Ward's research examines persistent inflammatory cardiovascular risk despite standard treatment. The related registered study uses immediate versus delayed icosapent ethyl and measures macrophage, inflammasome and immunosenescence biology in people with established cardiovascular disease, with or without type 2 diabetes.
Primary source ↗
2026Peer-reviewed clinical trial protocolPeer-reviewed protocol published July 3, 2026; NUS PROMETHEUS advanced to the Top 20 XPRIZE Healthspan finals in August 2026
PROMETHEUS Clinical Trial Protocol: Tailoring Healthy Ageing with Lifestyle and Nutraceuticals
NUS Academy for Healthy Longevity, National University of Singapore
The published protocol states that DoNotAge.org provided SIRT6Activator used in the study. The study is funded by the XPRIZE Foundation and National University of Singapore.
PROMETHEUS is a multimodal healthy-ageing protocol that includes 2.4 g/day SIRT6Activator alongside exercise, dietary and sleep interventions, whey protein, creatine and other personalized components. Because the intervention is multimodal, outcomes cannot isolate SIRT6Activator efficacy.
Primary source ↗
2026Company-hosted randomized trial reportCompany-hosted report; independent peer-reviewed publication not verified
DoNotAge Finished-Formulation Trial 1 — Well-Being, Fatigue and GI Tolerability
DoNotAge.org
The finished DoNotAge daily formulation was tested, and the report is authored/hosted by the DoNotAge.org Research Team on a DoNotAge-owned site.
The hosted report describes a 60-day randomized, double-blind, placebo-controlled study with 30 enrolled participants and 28 completers, measuring WHO-5 well-being, FACIT-Fatigue and GI outcomes.
Primary source ↗
2026Company-hosted randomized pilot reportCompany-hosted pilot report; independent peer-reviewed publication not verified
DoNotAge Finished-Formulation Trial 2 — Whole Blood NAD+ Pilot
DoNotAge.org
DoNotAge.org recruited/enrolled participants, provided the finished formulation and placebo, and monitored adherence; whole-blood NAD+ analysis is described as performed by LifeLab1 as an independent laboratory service provider.
The hosted report describes a 28-day randomized, double-blind, placebo-controlled pilot in 24 enrolled healthy adults, with 19 completers, assessing whole-blood NAD+ levels.
Primary source ↗
2026Registered randomized double-masked placebo-controlled interventional studyRecruiting; no results posted in the latest ClinicalTrials.gov record verified October 10, 2026
Effects of Quercetin Supplementation on Cardiometabolic Parameters — NCT06230861
University of Central Lancashire
ClinicalTrials.gov lists DoNotAge.org as a collaborator; the University of Central Lancashire is the sponsor.
ClinicalTrials.gov describes an estimated 40-participant randomized, parallel, double-masked study testing quercetin against placebo with systolic blood pressure as a primary outcome and additional cardiometabolic, wellbeing and sleep measures. DoNotAge.org is listed as collaborator; no results are posted in the registry record.
Primary source ↗
2026Preclinical replication experimentOngoing preclinical replication. The first 2026 composition did not reproduce a significant grip-strength/rejuvenation effect; protocol ambiguities were later clarified and additional rat work was planned for November 2026, with separate mouse work also planned.
ICR–Unicamp Rat Rejuvenation Replication Experiment
Rejuvenation Science Institute (ICR) and University of Campinas (Unicamp)
ICR states that DoNotAge.org committed US$25,000 toward the rat rejuvenation experiment and describes DoNotAge.org as a project partner.
DoNotAge contributed US$25,000 to this ICR/Unicamp replication effort. The first old-rat test in 2026 did not show a significant grip-strength advantage versus controls. Later clarification of preparation, fraction-selection and dosing details prompted plans for further replication rather than a claim of successful reproduction.
Primary source ↗
2026Prospective observational single-arm real-world cohortReal-world observational study published May 2026; not randomized, blinded or placebo-controlled
DoNotAge SureSleep 21-Day Real-World Customer Study
BioStackr / commissioned by DoNotAge.org
DoNotAge.org commissioned the study in existing SureSleep customers. The company study page states that BioStackr designed the protocol, managed data collection, set exclusion rules and performed the analysis, with no commission or affiliate revenue from SureSleep sales.
The published study page describes 60 confirmed participants and 51 analysed completers across 13 countries, with 1,472 daily check-ins over 21 days. Outcomes were self-reported and compared each participant's final five days with their own baseline. The study had no placebo arm, randomisation or blinding.
Primary source ↗
2026Prospective preclinical aged-mouse interventionFunded/planned prospective preclinical aged-mouse intervention; no outcomes reported as of October 10, 2026
DoNotAge-Funded PS18 Exercise-Mimetic Study in Aged Mice
USC Leonard Davis School of Gerontology / Cortes Lab
DoNotAge funded the aged-mouse experimental step presented by Constanza Cortes at DoNotAge Conference 2026. The project tests the prosaposin-derived peptide PS18 against sedentary control and treadmill exercise; it is not a human trial.
Conference materials describe an eight-week DoNotAge-funded aged-mouse experiment comparing sedentary vehicle control, sedentary PS18 and treadmill exercise, with frailty/healthspan, cognition, metabolic, body-composition and tissue outcomes. Published Cortes-lab skeletal-muscle TFEB/muscle-to-brain studies provide mechanistic rationale but are separate experiments and do not constitute PS18 efficacy results.
Primary source ↗
2025Randomized double-blind placebo-controlled human trial187 participants randomized; 48-week intervention; peer-reviewed protocol published; final peer-reviewed results not verified as of October 10, 2026
POLYamine Treatment in Elderly Patients With Coronary Artery Disease (POLYCAD) — NCT06186102
Aarhus University Hospital
The peer-reviewed POLYCAD protocol states that DoNotAge donated the spermidine intervention and placebo capsules and had no role in the study design, conduct, analysis or reporting.
POLYCAD randomizes 187 adults aged 65 years or older with coronary artery disease to 24 mg/day spermidine or placebo for 48 weeks. Co-primary outcomes include left-ventricular mass by cardiac MRI, VO2peak, appendicular lean mass and hs-CRP.
Primary source ↗
2026Ongoing placebo-controlled human study (conference-reported)Ongoing human study; separate registry or peer-reviewed protocol not identified in the sources reviewed as of October 10, 2026
Pure Spermidine and Muscle Regeneration in Older Adults — Aarhus University
Aarhus University
The official DoNotAge Conference 2026 archive says the study compares DoNotAge Pure Spermidine with placebo and lists DoNotAge support as research ingredients and matching placebo.
The conference archive describes a placebo-controlled study in older adults using leg-muscle samples and strength testing to investigate whether Pure Spermidine may influence age-related muscle repair biology.
Primary source ↗
2026Randomized quadruple-masked placebo-controlled human trialRecruiting as of the latest verified 2026 registry information
Project SIRT6 Activator — NCT07500649
NUS Academy for Healthy Longevity
ClinicalTrials.gov lists DoNotAge.org among the collaborators. The NUS participant-information document names Alan Graves as an external NUS co-investigator associated with DoNotAge.org.
Project SIRT6 Activator is a six-month randomized, placebo-controlled Singapore study in 60 prefrail men aged 50–80 evaluating fucoidan/SIRT6 Activator against placebo, including DNA-methylation and biological-age measures.
Primary source ↗
2026Human clinical study announced by DoNotAge; later conference-reported as ongoingAnnounced as an upcoming 24-week older-adult clinical study in a DoNotAge video and later described as ongoing at the September 2026 conference. Independent confirmation of trial registration, protocol, recruitment/start status or results has not been identified as of October 10, 2026.
DoNotAge Performance Healthy-Ageing Human Study
In a DoNotAge video, Scientific Advisory Board member Sergej M. Ostojic described preparations for a 24-week older-adult clinical study of the DoNotAge Performance formulation. The later DoNotAge Conference 2026 archive described the Performance healthy-ageing research as ongoing.
The first-party study description outlines a 24-week clinical study in older adults testing the multi-ingredient DoNotAge Performance formulation, which contains creatine alongside other compounds. Stated outcome areas include telomere length plus physical, functional and metabolic measures; the later conference archive also identifies inflammation, brain function and physical performance among the research outcomes.
Primary source ↗
